Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (290)	12/8/1998 3:34:00 PM
From: nigel bates	Read Replies (1) \| Respond to of 1073

>>$28 is not a target<< Pessimist. Another near miss from CTIC biz.yahoo.com >>....Lisofylline treated patients had a lower incidence of acute graft-versus-host disease (GVHD) than did control patients and this was highly significant in those patients at greatest risk for GVHD: those over the age of 40 and those that received higher intensity anti-cancer therapy. He underscored that important imbalances in risk factors between the placebo and lisofylline groups may have resulted in the failure to achieve a significant effect on the study's primary endpoints of infection and mortality.<< nig